22 results
8-K
EX-10.1
PCRX
Pacira BioSciences Inc
3 Apr 23
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using
8:02am
be true and correct in all material respects (or if qualified by materiality or Material Adverse Effect, in all respects) on and as of the date … material respects (provided that any representation or warranty that is qualified by materiality or Material Adverse Effect shall be true and correct in all
8-K
EX-10.1
PCRX
Pacira BioSciences Inc
9 Dec 21
Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
8:15am
be true and correct in all material respects (or if qualified by materiality or Material Adverse Effect, in all respects) on and as of the date … material respects (provided that any representation or warranty that is qualified by materiality or Material Adverse Effect shall be true and correct
SC TO-T
EX-99
FLXN
Flexion Therapeutics Inc
22 Oct 21
Third party tender offer statement
6:03am
of representations and warranties made by Flexion in the Merger Agreement, subject to the materiality and other qualifications set forth in the Merger Agreement … or a change in percentage of securities sought, will depend upon the facts and circumstances, including the relative materiality of the terms or information
SC TO-C
PCRX
Pacira BioSciences Inc
12 Oct 21
Information about tender offer
6:08am
Agreement were made as of a specified date, may be subject to a contractual standard of materiality different from what might be viewed as material … (disregarding for this purpose all “Material Adverse Effect” and “materiality” qualifications contained in such representations and warranties) in all
8-K
th7ncsxclq wl
12 Oct 21
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
6:06am
8-K
EX-2.1
rwxpfazcmu9z7rg9fs9
12 Oct 21
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
6:06am
8-K
EX-2.1
tugc6ix
5 Mar 19
Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control
7:30am
8-K
cvj4d lxsx
5 Mar 19
Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control
7:30am
8-K
EX-1.1
ziau92k6
9 Apr 14
Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12:00am
8-K
EX-1.1
5vwfiylsc ik
12 Apr 12
Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock
12:00am
424B4
y31rhz qb1
3 Feb 11
Prospectus supplement with pricing info
12:00am
S-1/A
EX-10.25
tbj41grio3qqe
3 Dec 10
IPO registration (amended)
12:00am
S-1/A
EX-10.26
qsd 0ldwvno
3 Dec 10
IPO registration (amended)
12:00am
S-1/A
pg4tssajf4
3 Dec 10
IPO registration (amended)
12:00am
S-1/A
EX-10.5
dcuovef01co
3 Dec 10
IPO registration (amended)
12:00am